Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Adoptive Cell Therapy Across Cancer Diagnoses
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Nivolumab Plus Ipilimumab in Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
- Status
- UNKNOWN
- Phase
- PHASE2